Kmira Zahra

Synchronous Thyroid and Gastric Mantle Cell Lymphoma

Kmira Zahra, Rania Bouneb, Sarra Mestiri, Mohamed Mahjoub, Monia Zaier, Yosra Ben Youssef & Abderrahim Khelif · International Journal of Medical and Pharmaceutical Case Reports · 2016

Introduction: Mantle cell lymphoma (MCL) is a distinct entity within the World Health Organization classification of lymphoid neoplasm and represents approximately 8% of lymphoma. Patients with mantle-cell lymphoma typically present with extensive disease and involvement of multi...

Open access Research Article 10.9734/IJMPCR/2016/29229

Primary Breast Lymphoma: A Study of 9 Cases

Olfa El Amine, Kmira Zahra, Azza Gabsi, Aida Goucha, Jamel Ben Hassouna, Khaled Rahal & Amor Gamoudi · Journal of Cancer and Tumor International · 2016

Aim: Non-Hodgkin's primary lymphoma of the breast is rare. These tumors represent 0.04 to 0.52% of malignant breast pathology, 2.2% of extranodal lymphoma and 0.4% of all non-Hodgkin’s lymphoma. Clinical and radiological aspects show no special characteristics. The aim of our stu...

Open access Research Article 10.9734/JCTI/2016/28910

Myocardial Infarction in a Young Patient with Chronic Myeloid Leukemia after Nilotinib Use

Neila Fathallah, Kmira Zahra, Rania Bouneb, Mohamed Mahjoub, Wafa Guetari, Monia Zaier, Chaker Ben Salem & Abderrahim Khelif · International Journal of Medical and Pharmaceutical Case Reports · 2016

Nilotinib is an analog of imatinib increasingly used for the treatment of imatinib-resistant chronic myeloid leukemia. It has been considered a well-tolerated drug with little side effects. The most common adverse effects to nilotinib are skin rash, pruritus, headache, nausea, an...

Open access Research Article 10.9734/IJMPCR/2016/28909